Merck and Moderna announced positive phase three trial results for an experimental mRNA cancer vaccine combined with Keytruda. The regimen significantly extended recurrence-free survival in over 1,100 high-risk melanoma patients, potentially marking a new treatment standard.
Merck and Moderna announced positive phase three trial results for their personalized mRNA cancer vaccine combined with Keytruda, showing improved recurrence-free survival in high-risk melanoma patients compared to immunotherapy alone.
A personalized mRNA vaccine combined with Keytruda significantly reduced the risk of melanoma recurrence and death in a clinical trial. The therapy, which trains T cells to target unique tumor neoantigens, showed 68.8% of patients remained cancer-free after five years, compared to 49.1% with Keytruda alone.
Merck reported first-quarter 2026 results exceeding Wall Street expectations with $16.29B revenue, driven by strong Keytruda sales of $8.03B (up 12%). The pharma giant narrowed its 2026 revenue guidance to $65.8B-$67B and raised adjusted earnings outlook to $5.04-$5.16 per share. The company posted a net loss of $4.24B due to a $3.62 per share charge from its Cidara Therapeutics acquisition, part of its strategy to offset upcoming generic competition for Keytruda in 2028 and diabetes drugs Januvia/Janumet later this year.
Hochpreisige Krebsmedikamente wie Keytruda belasten das deutsche Gesundheitssystem zunehmend. Pharmakonzerne nutzen regulatorische Spielräume aus, was die Finanzierbarkeit der Krankenkassen gefährdet.
Daniel Goldstein hat eine Überdosierung des Krebsmedikaments Keytruda aufgedeckt. Der Hersteller erzielt damit Milliarden, was zu einem Konflikt mit dem Mediziner führt.
Das Krebsmedikament Keytruda (Pembrolizumab) bietet vielen Patienten wie Josephina Kersten neue Hoffnung. Allerdings belasten die von Pharmafirmen wie MSD künstlich hoch gehaltenen Preise das deutsche Gesundheitssystem und die Beitragszahler.
